Immutep Ltd ADR (IMMP)

$0.47 -0.02 (-3.98%)
Market Cap 71.42M
Revenue (ttm) 6.69M
Net Income (ttm) -39.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -594.62%
Debt to Equity Ratio 0.01
Volume 6,829,755
Avg Vol 1,143,986
Day's Range N/A - N/A
Shares Out 147.37M
Stochastic %K 1%
Beta 1.77
Analysts Sell
Price Target $9.67

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 2 8315 7003
Fax: 61 2 8569 1880
Address:
Australia Square, Level 32 264 George Street, Sydney, Australia
Messerschmittbf109
Messerschmittbf109 Mar. 16 at 5:53 PM
$IMMP It's worth 0.45 for the cash ...but next time .burning .. it will be worth 0.40. Unfortunately, I think it will have to be diluted and merged unless we do some sleight of hand in phase 1. They've disappointed once again. In 20 years, only a few days of joy have passed.
0 · Reply
Mkm950
Mkm950 Mar. 16 at 5:38 PM
$IMMP
0 · Reply
rispi
rispi Mar. 16 at 4:57 PM
$IMMP and still missing Dr.Reddy statement about the capitulation
0 · Reply
Motorhhead
Motorhhead Mar. 16 at 4:28 PM
$CODX $SGN $IMMP $AIDX It's uncanny the beautiful short plays this person offers on a daily basis! https://stocktwits.com/beppels/message/647604491
0 · Reply
rispi
rispi Mar. 16 at 4:13 PM
$IMMP It took a couple hours to get target, job done
0 · Reply
rispi
rispi Mar. 16 at 4:11 PM
$IMMP first step from the CEO is to announce How much will the shoutdown of TACT-004 will cost. Do you all know that Marc cannot simply close the trial? there are people, lifes and therapeutic protocols. After that we'll see how much money left for TACT-003 and the timeline. For sure they gonna run into a r/s BUT the point is at what sharprice they will arrive before it. Could be .20 in 6 months. the market now and in the future has zero confidence, and it is the worst sentiment in the stock market. I told you mpnths, years ago, it was clear just catching how the CEO approach to offering share and PR.
0 · Reply
ScienceBling
ScienceBling Mar. 16 at 3:57 PM
$IMMP Unfortunately incompetent IMMP leader-less-ship usually ends very poorly... Go to SLS for much smarter CEO and AML CURE!!!
0 · Reply
AshvsEvilDead
AshvsEvilDead Mar. 16 at 3:53 PM
$IMMP with that much COH I would announce that combo strategy with IL15 (Anktiva) like now. Pivot and watch this explode.
0 · Reply
Arctarus
Arctarus Mar. 16 at 3:49 PM
$IMMP wow.... this is what I call a yuge overeaction!!!!!
0 · Reply
Trissy08
Trissy08 Mar. 16 at 3:45 PM
$IMMP what happens now with this one after the phase 3 trial termination?
0 · Reply
Latest News on IMMP
Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mon, 16 Mar 2026 08:03:00 -0400 - 8 hours ago

Immutep Limited Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Fri, 06 Feb 2026 08:00:00 -0500 - 5 weeks ago

Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC

Immutep Quarterly Activities Report Q2 FY26

Thu, 29 Jan 2026 08:00:00 -0500 - 6 weeks ago

Immutep Quarterly Activities Report Q2 FY26

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

Mon, 22 Dec 2025 08:00:00 -0500 - 3 months ago

Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Mon, 08 Dec 2025 02:34:15 -0500 - 3 months ago

India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug

Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa

2025-12-08T07:28:15.000Z - 3 months ago

Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa

Immutep Limited (IMMP) Presents at ESMO Congress 2025 - Slideshow

2025-10-20T23:02:57.000Z - 5 months ago

Immutep Limited (IMMP) Presents at ESMO Congress 2025 - Slideshow

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Mon, 20 Oct 2025 08:01:00 -0400 - 5 months ago

Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Mon, 08 Sep 2025 08:00:00 -0400 - 6 months ago

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

Immutep Quarterly Activities Report Q4 FY25

Wed, 30 Jul 2025 08:00:00 -0400 - 8 months ago

Immutep Quarterly Activities Report Q4 FY25

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Tue, 29 Jul 2025 08:00:00 -0400 - 8 months ago

Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Tue, 27 May 2025 08:00:00 -0400 - 10 months ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Thu, 15 May 2025 15:50:04 -0400 - 10 months ago

Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo

Immutep Limited: Surging On Positive Head And Neck Data

2025-05-08T12:46:59.000Z - 11 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep to Participate in Upcoming Investor Conferences

Wed, 02 Apr 2025 08:00:00 -0400 - 1 year ago

Immutep to Participate in Upcoming Investor Conferences

Immutep Quarterly Activities Report Q2 FY25

Fri, 31 Jan 2025 08:00:00 -0500 - 1 year ago

Immutep Quarterly Activities Report Q2 FY25

Immutep Limited: Continuing To Make The Case For Eftilagimod

2025-01-28T21:37:29.000Z - 1 year ago

Immutep Limited: Continuing To Make The Case For Eftilagimod

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Tue, 17 Dec 2024 08:00:00 -0500 - 1 year ago

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Thu, 12 Dec 2024 08:15:00 -0500 - 1 year ago

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Fri, 15 Nov 2024 15:18:16 -0500 - 1 year ago

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Thu, 14 Nov 2024 11:16:11 -0500 - 1 year ago

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Thu, 14 Nov 2024 08:15:00 -0500 - 1 year ago

Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

Immutep Quarterly Activities Report Q1 FY25

Tue, 29 Oct 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q1 FY25

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Thu, 10 Oct 2024 08:00:00 -0400 - 1 year ago

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

Immutep: Navigating The Bumps In The Road

Mon, 07 Oct 2024 09:10:11 -0400 - 1 year ago

Immutep: Navigating The Bumps In The Road

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Mon, 16 Sep 2024 08:00:00 -0400 - 1 year ago

Immutep's Efti in Combination with MSD's KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

Immutep Ltd Clinical Results Webinar Transcript

2024-09-14T11:19:07.000Z - 1 year ago

Immutep Ltd Clinical Results Webinar Transcript

Immutep Ltd Webcast Presentation Transcript

2024-09-14T11:19:05.000Z - 1 year ago

Immutep Ltd Webcast Presentation Transcript

Immutep Quarterly Activities Report Q4 FY24

Wed, 31 Jul 2024 08:00:00 -0400 - 1 year ago

Immutep Quarterly Activities Report Q4 FY24

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Mon, 15 Jul 2024 13:54:02 -0400 - 1 year ago

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Thu, 11 Jul 2024 18:40:00 -0400 - 1 year ago

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Wed, 03 Jul 2024 08:00:00 -0400 - 1 year ago

Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Tue, 25 Jun 2024 08:00:00 -0400 - 1 year ago

Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer

Immutep successfully completes institutional placement and institutional component of entitlement offer

Wed, 05 Jun 2024 06:00:00 -0400 - 1 year ago

Immutep successfully completes institutional placement and institutional component of entitlement offer

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Sun, 02 Jun 2024 20:38:00 -0400 - 1 year ago

Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Wed, 15 May 2024 08:00:00 -0400 - 1 year ago

Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Thu, 02 May 2024 08:00:00 -0400 - 2 years ago

Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

Wed, 01 May 2024 12:39:01 -0400 - 2 years ago

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Quarterly Activities Report Q3 FY24

Mon, 29 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Quarterly Activities Report Q3 FY24

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Wed, 24 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Thu, 18 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Wed, 17 Apr 2024 08:00:00 -0400 - 2 years ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Tue, 05 Mar 2024 08:00:00 -0500 - 2 years ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Immutep Quarterly Activities Report Q2 FY24

Tue, 30 Jan 2024 08:00:00 -0500 - 2 years ago

Immutep Quarterly Activities Report Q2 FY24

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Thu, 04 Jan 2024 08:00:00 -0500 - 2 years ago

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Wed, 03 Jan 2024 17:04:38 -0500 - 2 years ago

Immutep: Upcoming Signals For 2024 (Maintain Buy)

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Thu, 21 Dec 2023 08:00:00 -0500 - 2 years ago

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Thu, 07 Dec 2023 08:00:00 -0500 - 2 years ago

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Wed, 22 Nov 2023 08:00:00 -0500 - 2 years ago

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Thu, 09 Nov 2023 08:00:00 -0500 - 2 years ago

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Nov 6, 2023, 8:00 AM EST - 2 years ago

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Nov 3, 2023, 12:00 PM EDT - 2 years ago

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep to Participate in November Investor Events

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Immutep to Participate in November Investor Events

Immutep Quarterly Activities Report Q1 FY24

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Immutep Quarterly Activities Report Q1 FY24

Messerschmittbf109
Messerschmittbf109 Mar. 16 at 5:53 PM
$IMMP It's worth 0.45 for the cash ...but next time .burning .. it will be worth 0.40. Unfortunately, I think it will have to be diluted and merged unless we do some sleight of hand in phase 1. They've disappointed once again. In 20 years, only a few days of joy have passed.
0 · Reply
Mkm950
Mkm950 Mar. 16 at 5:38 PM
$IMMP
0 · Reply
rispi
rispi Mar. 16 at 4:57 PM
$IMMP and still missing Dr.Reddy statement about the capitulation
0 · Reply
Motorhhead
Motorhhead Mar. 16 at 4:28 PM
$CODX $SGN $IMMP $AIDX It's uncanny the beautiful short plays this person offers on a daily basis! https://stocktwits.com/beppels/message/647604491
0 · Reply
rispi
rispi Mar. 16 at 4:13 PM
$IMMP It took a couple hours to get target, job done
0 · Reply
rispi
rispi Mar. 16 at 4:11 PM
$IMMP first step from the CEO is to announce How much will the shoutdown of TACT-004 will cost. Do you all know that Marc cannot simply close the trial? there are people, lifes and therapeutic protocols. After that we'll see how much money left for TACT-003 and the timeline. For sure they gonna run into a r/s BUT the point is at what sharprice they will arrive before it. Could be .20 in 6 months. the market now and in the future has zero confidence, and it is the worst sentiment in the stock market. I told you mpnths, years ago, it was clear just catching how the CEO approach to offering share and PR.
0 · Reply
ScienceBling
ScienceBling Mar. 16 at 3:57 PM
$IMMP Unfortunately incompetent IMMP leader-less-ship usually ends very poorly... Go to SLS for much smarter CEO and AML CURE!!!
0 · Reply
AshvsEvilDead
AshvsEvilDead Mar. 16 at 3:53 PM
$IMMP with that much COH I would announce that combo strategy with IL15 (Anktiva) like now. Pivot and watch this explode.
0 · Reply
Arctarus
Arctarus Mar. 16 at 3:49 PM
$IMMP wow.... this is what I call a yuge overeaction!!!!!
0 · Reply
Trissy08
Trissy08 Mar. 16 at 3:45 PM
$IMMP what happens now with this one after the phase 3 trial termination?
0 · Reply
MrMaxxxx
MrMaxxxx Mar. 16 at 3:36 PM
$IMMP $85,000,000.00 CASH Almost no DEBT! What are you taking!?
1 · Reply
Gunnar1
Gunnar1 Mar. 16 at 3:26 PM
$IMMP Slowly nibbling here and there...
1 · Reply
Biotoneten
Biotoneten Mar. 16 at 2:45 PM
$IMMP Brpkers flushing out margin
0 · Reply
rispi
rispi Mar. 16 at 2:17 PM
$IMMP can't hear the king of fake savvy guru anymore 75% green light???
0 · Reply
Golferhack12
Golferhack12 Mar. 16 at 1:56 PM
$IMMP still overvalued don't let the penny stock fool you you can go lower
0 · Reply
dublenaught
dublenaught Mar. 16 at 1:54 PM
$IMMP you cannot short stocks below a dollar....
1 · Reply
LarryFin
LarryFin Mar. 16 at 1:50 PM
$IMMP yes, i love it - what a nice „Short“ 🤩
0 · Reply
Arctarus
Arctarus Mar. 16 at 1:49 PM
$IMMP -84% and counting. Complete mess
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Mar. 16 at 1:48 PM
$IMMP $0.30ish coming soon!!
0 · Reply
Sanjaynaik2011
Sanjaynaik2011 Mar. 16 at 1:47 PM
$IMMP Looks like $IMMP has become itself a deadly Cancerous!!!
0 · Reply
Headofhero23
Headofhero23 Mar. 16 at 1:39 PM
$IMMP 1 usd this week ? I looking forward to See the results from this study? If its possible that they Change her mind from the halt?
0 · Reply
LarryFin
LarryFin Mar. 16 at 1:36 PM
$IMMP the next short party. And it goes down, down, down. 😂
0 · Reply